TRANSGENE (ENX:TNG) Successfully Completes Rights Issue And Private Placement
3/25/2014 8:00:37 AM
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, announces that it has raised a total of €65.5 million via a two-step capital increase.
Help employers find you! Check out all the jobs and post your resume.
comments powered by